NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $16.96 -0.40 (-2.28%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Structure Therapeutics Stock (NASDAQ:GPCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Structure Therapeutics alerts:Sign Up Key Stats Today's Range$16.97▼$17.9550-Day Range$17.36▼$39.5552-Week Range$16.97▼$94.90Volume141,322 shsAverage Volume965,002 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$110.91Consensus RatingModerate Buy Company Overview Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease. Founded in 2016, the company has operations in the United States and China. Raymond Stevens, Ph.D., a co-founder of the company, serves as its chief executive officer.AI Generated. May Contain Errors. Read More Structure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreGPCR MarketRank™: 3.52832512315 of 5 starsStructure Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 713th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingStructure Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialStructure Therapeutics has a consensus price target of $110.91, representing about 538.9% upside from its current price of $17.36.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Structure Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.44) per share.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.01% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 17.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.55 News SentimentStructure Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.Search Interest12 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.50% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GPCR Stock News HeadlinesStructure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?November 16 at 11:50 PM | finance.yahoo.comHC Wainwright Has Negative Opinion of GPCR FY2026 EarningsNovember 16 at 1:33 AM | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)Analysts Offer Predictions for GPCR Q1 EarningsNovember 15, 2026 | americanbankingnews.comStructure Q3 Loss Widens On Higher R&D Costs; Three Aleniglipron Readouts Due In Q4November 10, 2026 | rttnews.comStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsNovember 9, 2026 | globenewswire.comStructure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNovember 4, 2026 | globenewswire.comStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026October 19, 2026 | globenewswire.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $69.55 at the beginning of the year. Since then, GPCR shares have decreased by 75.0% and is now trading at $17.36. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.15. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Top institutional investors of Structure Therapeutics include B Group Inc. (0.26%), HighVista Strategies LLC (0.24%), Healthcare of Ontario Pension Plan Trust Fund (0.19%) and Jefferies Financial Group Inc. (0.18%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Palantir Technologies (PLTR), SoundHound AI (SOUN), Viking Therapeutics (VKTX), SLB (SLB) and Symbotic (SYM). Company Calendar Last Earnings11/09/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GPCR's financial health is in the Red zone, according to TradeSmith. GPCR has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GPCR CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees281Year FoundedN/APrice Target and Rating Average Price Target for Structure Therapeutics$110.91 High Price Target$145.00 Low Price Target$70.00 Potential Upside/Downside+544.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$141.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.18% Return on Assets-27.62% Debt Debt-to-Equity RatioN/A Current Ratio11.90 Quick Ratio11.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.45 per share Price / Book0.99Miscellaneous Outstanding Shares70,030,000Free Float66,178,000Market Cap$1.20 billion OptionableOptionable Beta-1.12 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GPCR) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.